Oral magnesium supplementation: An adjuvant alternative to facing the worldwide challenge of type 2 diabetes?;Suplementos orales con sales de magnesio: ¿son útiles como coadyuvantes ante el desafío de salud que representa la diabetes tipo 2?

Cirugia y Cirujanos

Volumn 82, Issue 3, 2014, Pages 282-289

  Guerrero Romero, Fernando ^a   Rodríguez Morán, Martha ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Clinical trial; Cohort; Diabetes; Glycemia; Magnesium

Indexed keywords

GLUCOSE BLOOD LEVEL; MAGNESIUM;

ANALYSIS; BLOOD; COHORT ANALYSIS; COMPLICATION; COST OF ILLNESS; DIABETES MELLITUS, TYPE 2; DIET; DIET SUPPLEMENTATION; ECONOMICS; GLUCOSE BLOOD LEVEL; HEALTH; HUMAN; INTERVENTION STUDY; MAGNESIUM DEFICIENCY; MEXICO; ORAL DRUG ADMINISTRATION; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; BLOOD GLUCOSE; COHORT STUDIES; COST OF ILLNESS; DIABETES MELLITUS, TYPE 2; DIET; DIETARY SUPPLEMENTS; GLOBAL HEALTH; HUMANS; INTERVENTION STUDIES; MAGNESIUM; MAGNESIUM DEFICIENCY; MEXICO; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84905250809     PISSN: 00097411     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. International Diabetes Federation. Atlas de Diabetes. Update 2012. 5th edición. (consultado 2013 octubre). Disponible en http://www.idf.org/ diabetesatlas/download-book
2. Castro V, Gómez-Dantés H, Negrete-Sánchez J, Tapia- Conyer R. Las enfermedades crónicas en las personas de 60-69 años. Salud Pública Méx 1996;38:438-447.
3. Hernández-Avila M, Gutierrez JP, Reynoso-Noverón N. Diabetes mellitus en México. El estado de la epidemia. Salud Publica Mex 2013;55(supl 2):S129-S136.
4. Rodríguez Bolaños R de L, Reynales Shigematsu LM, Jiménez Ruíz JA, Juárez Márquez SA, Hernández Ávila M. Costos directos de atención médica en pacientes con diabetes mellitus tipo 2 en México: análisis de microcosteo. Rev Panam Salud Publica 2010;28:412-420.
5. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of Diet and Exercise in Preventing NIDDM in People With Impaired Glucose Tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-544. Doi: 10.2337/diacare.20.4.537
6. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Finnish Diabetes Prevention Study Group. Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance. N Engl J Med 2001;344:1343-1350. DOI: 10.1056/nejm200105033441801
7. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
8. Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to preventtype 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Diabetes Care 1998;21:1720-1725.
9. Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA. TRIPOD (Troglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 1998;19:217-231.
10. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-161.
11. Subsecretaria de Prevención y Promoción de la Salud y Dirección General de Epidemiología de la Secretaría de Salud. Boletín Epidemiológico Diabetes Mellitus Tipo 2.: Primer Trimestre-2013. (consultado 2013 octubre 7). Disponible en http://www. epidemiologia.salud.gob.mx/doctos/infoepid/bol-diabetes/dm2-bol1-2013.pdf
12. Lopez Martinez J, Sanchez Castilla M, Garcia de Lorenzo y Mateos A, Culebras Fernandez JM. Magnesium: metabolism and requirements. Nutr Hosp 1997;12:4-14.
13. Paolisso G, Scheen A, D'Onofrio F, Lefèbvre P. Magnesium and glucose homeostasis. Diabetologia 1990;33:511-514.
14. Guerrero-Romero F, Rodríguez-Morán M. Relationship between serum magnesium levels and C-reactive protein concentration, in non-diabetic, non-hypertensive obesesubjects. Int J Obes Relat Metab Disord 2002;26:469-474.
15. Song Y, Li TY, van Dam RM, Manson JE, Hu FB. Magnesium intake and plasma concentrations of markers of systemicinflammation and endothelial dysfunction in women. AmJ Clin Nutr 2007;85:1068-1074.
16. Kim DJ, Xun P, Liu K, Loria C, Yokota K, Jacobs DR Jr, et al. Magnesium intake in relation to systemic inflammation, insulin resistance, and the incidence of diabetes. Diabetes Care 2010;33:2604-2610.
17. Rosolova H, Mayer O, Jr Reaven GM. Insulin-mediated glucose disposal is decreased in normal subjects with relatively low plasma magnesium concentrations. Metabolism 2000;49:418-420.
18. Mejía-Rodríguez F, Shamah-Levy T, Villalpando S, García- Guerra A, Méndez-Gómez Humarán I. Iron, zinc, copper and magnesium deficiencies in Mexican adults from the National Health and Nutrition Survey 2006. Salud Publica Mex 2013;55:275-284.
19. Kao WH, Folsom AR, Nieto FJ, Mo JP, Watson RL, Brancati FL. Serum and dietary magnesium and the risk for type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. Arch Intern Med 1999;159:2151-2159.
20. Rumawas ME, McKeown NM, Rogers G, Meigs JB, Wilson PW, Jacques PF. Magnesium intake is related to improved insulin homeostasis in the Framingham offspring cohort. J Am Coll Nutr 2006;25:486-492.
21. Hopping BN, Erber E, Grandinetti A, Verheus M, Kolonel LN, Maskarinec G. Dietary fiber, magnesium, and glycemic load alter risk of type 2 diabetes in a multiethnic cohort in Hawaii. J Nutr 2010;140:68-74.
22. Lopez-Ridaura R, Willett WC, Rimm EB, Liu S, Stampfer MJ, Manson JE, et al. Magnesium intake and risk of type 2 diabetes in men and women. Diabetes Care. 2004;27:134-140.
23. Kirii K, Iso H, Date C, Fukui M, Tamakoshi A, JACC Study Group. Magnesium intake and risk of self-reported type 2 diabetes among Japanese. J Am Coll Nutr 2010;29:99-106.
24. Nanri A, Mizoue T, Noda M, Takahashi Y, Kirii K, Inoue M, et al. Japan Public Health Center-based Prospective Study Group. Magnesium intake and type II diabetes in Japanese men and women: the Japan Public Health Center-based Prospective Study. Eur J Clin Nutr 2010;64:1244-1247.
25. Song Y, Manson JE, Buring JE, Liu S. Dietary magnesium intake in relation to plasma insulin levels and risk of type 2 diabetes in women. Diabetes Care 2004;27:59-65.
26. Schulze MB, Schulz M, Heidemann C, Schienkiewitz A, Hoffmann K, Boeing H. Fiber and magnesium intake and incidence of type 2 diabetes: a prospective study and meta-analysis. Arch Intern Med 2007;167:956-965.
27. Guerrero-Romero F, Rascón-Pacheco RA, Rodríguez- Morán M, Escobedo de la Peña J, Wacher N. Hypomagnesemia and risk for metabolic glucose disorders: A 10-y follow-up study. Eur J Clin Invest 2008;38:389-396.
28. Guerrero-Romero F, Rodríguez-Morán M. Magnesium improves the beta-cell function to compensate variation of insulin sensitivity: double-blind, randomized clinical trial. Eur J Clin Invest 2011;41:405-410.
29. Mooren FC, Krüger K, Völker K, Golf SW, Wadepuhl M, Kraus A. Oral magnesium supplementation reduces insulin resistance in non-diabetic subjects - a double-blind, placebo-controlled, randomized trial. Diabetes Obes Metab 2011;13:281-224.
30. Guerrero-Romero F, Tamez-Perez HE, González-González G, Salinas-Martínez AM, Montes-Villarreal J, Treviño-Ortiz JH, et al. Oral magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance. A double-blind placebo-controlled randomized trial. Diabetes Metab 2004;30:253-258.
31. Chacko SA, Sul J, Song Y, Li X, LeBlanc J, You Y, et al. Magnesium supplementation, metabolic and inflammatory markers, and global genomic and proteomic profiling: a randomized, double-blind, controlled, crossover trial in overweight individuals. Am J Clin Nutr 2011;93:463-473.
32. Paolisso G, Sgambato S, Gambardella A, Pizza G, Tesauro P, Varricchio M, et al. Daily magnesium supplements improve glucose handling in elderly subjects. Am J Clin Nutr 1992;55:1161-1167.
33. Rodríguez-Morán M, Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized doubleblind controlled trial. Diabetes Care 2003;26:1147-1152.
34. Purvis JR, Cummings DM, Landsman P, Carroll R, Barakat H, Bray J, et al. Effect of oral magnesium supplementation on selected cardiovascular risk factors in non-insulindependent diabetics. Arch Fam Med 1994;3:503-508.
35. de Lordes Lima M, Cruz T, Pousada JC, Rodrigues LE, Barbosa K, Canguçu V. The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes. Diabetes Care 1998;21:682-686.
36. Johnsen SP, Husted SE, Ravn HB, Stødkilde-Jørgensen H, Peltz-Andresen E, Christensen CK. supplementation to patients with type II diabetes Ugeskr Laeger 1999;161:945-948.
37. de Valk HW, Verkaaik R, van Rijn HJ, Geerdink RA, Struyvenberg A. Oral magnesium supplementation in insulin-requiring Type 2 diabetic patients. Diabet Med 1998;15:503-507.
38. Gullestad L, Jacobsen T, Dolva LO. Effect of magnesium treatment on glycemic control and metabolic parameters in NIDDM patients. Diabetes Care 1994;17:460-461.
39. Saris NE, Mervaala E, Karppanen H, Khawaja JA, Lewenstam A. Magnesium; an update on physiological, clinical and analytical aspects. Clin Chem Acta 2000;294:1-26.
40. Cakmak I, Yazici AM. Magnesium: A Forgotten Element in Crop Production. Better Crops 2010;94:23-25.
41. Jones JE, Manalao R, Flink EB. Magnesium Requirements in Adults. Am J Clin Nutr 1967;20:632-635.
42. White JR Jr, Campbell RK. Magnesium and diabetes: a review. Ann Pharmacother 1993;27:775-780.